Tailored immunoconjugate therapy depending on a quantity of tumor stroma

Cancer Science

Volumn 104, Issue 2, 2013, Pages 231-237

  Yasunaga, Masahiro ^a   Manabe, Shino ^b   Tarin, David ^c   Matsumura, Yasuhiro ^a  

^a NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

^b RIKEN   (Japan)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY CONJUGATE; CARBOXYLESTERASE; COLLAGEN TYPE 4; FIRTECAN;

ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; FEMALE; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; LYMPHOMA; MOUSE; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; THERAPY EFFECT; TREATMENT OUTCOME;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CAMPTOTHECIN; CELL LINE, TUMOR; COLLAGEN; FEMALE; HUMANS; IMMUNOCONJUGATES; LYMPHOMA; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASTIC STEM CELLS; PANCREATIC NEOPLASMS; TOPOISOMERASE I INHIBITORS;

EID: 84873706151     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/cas.12062     Document Type: Article

References (41)

1. Imai K, Takaoka A. Comparing antibody and small-molecule therapies for cancer. Nat Rev Cancer 2006; 6: 714-27.
2. Matsumura Y, Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res 1986; 46: 6387-92.
3. Duncan R. The dawning era of polymer therapeutics. Nat Rev Drug Discov 2003; 2: 347-60.
4. Matsumura Y, Kataoka K. Preclinical and clinical studies of anticancer agent-incorporating polymer micelles. Cancer Sci 2009; 100: 572-9.
5. Ricart AD, Tolcher AW. Technology insight: cytotoxic drug immunoconjugates for cancer therapy. Nat Clin Pract Oncol 2007; 4: 245-55.
6. Doronina SO, Toki BE, Torgov MY et al. Development of potent monoclonal antibody auristatin conjugates for cancer therapy. Nat Biotechnol 2003; 21: 778-84.
7. Wu AM, Senter PD. Arming antibodies: prospects and challenges for immunoconjugates. Nat Biotechnol 2005; 23: 1137-46.
8. Doronina SO, Bovee TD, Meyer DW et al. Novel peptide linkers for highly potent antibody-auristatin conjugate. Bioconjug Chem 2008; 19: 1960-3.
9. Koenders PG, Peters WH, Wobbes T, Beex LV, Nagengast FM, Benraad TJ. Epidermal growth factor receptor levels are lower in carcinomatous than in normal colorectal tissue. Br J Cancer 1992; 65: 189-92.
10. Messersmith W, Oppenheimer D, Peralba J et al. Assessment of epidermal growth factor receptor (EGFR) signaling in paired colorectal cancer and normal colon tissue samples using computer-aided immunohistochemical analysis. Cancer Biol Ther 2005; 4: 1381-6.
11. Hayden E. Cancer complexity slows quest for cure. Nature 2006; 455: 148.
12. Heng HH, Bremer SW, Stevens JB, Ye KJ, Liu G, Ye CJ. Genetic and epigenetic heterogeneity in cancer: a genome-centric perspective. J Cell Physiol 2009; 220: 538-47.
13. Collins BE, Blixt O, Han S et al. High-affinity ligand probes of CD22 overcome the threshold set by cis ligands to allow for binding, endocytosis, and killing of B cells. J Immunol 2006; 177: 2994-3003.
14. Schmidt MM, Thurber GM, Wittrup KD. Kinetics of anti-carcinoembryonic antigen antibody-internalization: effects of affinity, bivalency, and stability. Cancer Immunol Immunother 2008; 57: 1879-90.
15. Burke PJ, Senter PD, Meyer DW et al. Design, synthesis, and biological evaluation of antibody-drug conjugates comprised of potent camptothecin analogues. Bioconjug Chem 2009; 20: 1242-50.
16. Coyne CP, Jones T, Pharr T. Synthesis of a covalent gemcitabine-(carbamate)-[anti-HER2/neu] immunochemotherapeutic and its cytotoxic anti-neoplastic activity against chemotherapeutic-resistant SKBr-3 mammary carcinoma. Bioorg Med Chem 2011; 19: 67-76.
17. Dvorak HF. Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N Engl J Med 1986; 315: 1650-9.
18. Minchinton AI, Tannock IF. Drug penetration in solid tumors. Nat Rev Cancer 2006; 6: 583-92.
19. Trédan O, Galmarini CM, Patel K, Tannock IF. Drug resistance and the solid tumor microenvironment. J Natl Cancer Inst 2007; 99: 1441-54.
20. Ghajar CM, Bissell MJ. Extracellular matrix control of mammary gland morphogenesis and tumorigenesis: insights from imaging. Histochem Cell Biol 2008; 130: 1105-18.
21. Yasunaga M, Manabe S, Tarin D, Matsumura Y. Cancer-stroma targeting therapy by cytotoxic immunoconjugate bound to the collagen 4 network in the tumor tissue. Bioconjug Chem 2011; 22: 1776-83.
22. Yasunaga M, Manabe S, Matsumura Y. New concept of cytotoxic immunoconjugate therapy targeting cancer-induced fibrin clots. Cancer Sci 2011; 102: 1396-402.
23. Ostermann E, Garin-Chesa P, Heider KH et al. Effective immunoconjugate therapy in cancer models targeting a serine protease of tumor fibroblasts. Clin Cancer Res 2008; 14: 4584-92.
24. Palumbo A, Hauler F, Dziunycz P et al. A chemically modified antibody mediates complete eradication of tumors by selective disruption of tumor blood vessels. Br J Cancer 2011; 104: 1106-15.
25. Armstrong A, Eck SL. EpCAM: a new therapeutic target for an old cancer antigen. Cancer Biol Ther 2003; 2: 320-6.
26. Iwamura T, Katsuki T, Ide K. Establishment and characterization of a human pancreatic cancer cell line (SUIT-2) producing carcinoembryonic antigen and carbohydrate antigen 19-9. Jpn J Cancer Res 1987; 78: 54-62.
27. Folli S, Westermann P, Braichotte D et al. Antibody-indocyanin conjugates for immunophotodetection of human squamous cell carcinoma in nude mice. Cancer Res 1994; 54: 2643-9.
28. Mariani G, Lasku A, Balza E et al. Tumor targeting potential of the monoclonal antibody BC-1 against oncofetal fibronectin in nude mice bearing human tumor implants. Cancer 1997; 80: 2378-84.
29. Senter PD, Beam KS, Mixan B, Wahl AF. Identification and activities of human carboxylesterases for the activation of CPT-11, a clinically approved anticancer drug. Bioconjug Chem 2001; 12: 1074-80.
30. Li B, Sedlacek M, Manoharan I et al. Butyrylcholinesterase, paraoxonase, and albumin esterase, but not carboxylesterase, are present in human plasma. Biochem Pharmacol 2005; 70: 1673-84.
31. Pommier Y, Topoisomerase I. inhibitors: camptothecins and beyond. Nat Rev Cancer 2006; 6: 789-802.
32. Zhao H, Rubio B, Sapra P et al. Novel prodrugs of SN38 using multiarm poly(ethylene glycol) linkers. Bioconjug Chem 2008; 19: 849-59.
33. Michel RB, Mattes MJ. Intracellular accumulation of the anti-CD20 antibody 1F5 in B-lymphoma cells. Clin Cancer Res 2002; 8: 2701-13.
34. Luqman M, Klabunde S, Lin K et al. The antileukemia activity of a human anti-CD40 antagonist antibody, HCD122, on human chronic lymphocytic leukemia cells. Blood 2008; 112: 711-20.
35. Lim SH, Vaughan AT, Ashton-Key M et al. Fc gamma receptor IIb on target B cells promotes rituximab internalization and reduces clinical efficacy. Blood 2011; 118: 2530-40.
36. Beers SA, French RR, Chan HTC et al. Antigenic modulation limits the efficacy of anti-CD20 antibodies: implications for antibody selection. Blood 2010; 115: 5191-201.
37. Sutherland R, Buchegger F, Schreyer M, Vacca A, Mach J-P. Penetration and binding of radiolabeled anti-carcinoembryonic antigen monoclonal antibodies and their antigen binding fragments in human colon multicellular tumor spheroids. Cancer Res 1987; 47: 1627-33.
38. Hamaguchi T, Doi T, Eguchi-Nakajima T et al. Phase I study of NK012, a novel SN-38-incorporating micellar nanoparticle, in adult patients with solid tumors. Clin Cancer Res 2010; 16: 5058-66.
39. Matsumura Y. Preclinical and clinical studies of NK012, an SN-38-incorpo-rating polymeric micelles, which is designed based on EPR effect. Adv Drug Deliv Rev 2011; 63: 184-92.
40. Matsumura Y. Cancer stromal targeting (CAST) therapy. Adv Drug Deliv Rev 2012; 64: 710-9.
41. Cunningham D, Humblet Y, Siena S et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004; 351: 337-45.